Humira biosimilar launches may serve as a test case for wider investments, Biosimilars Forum leader cautions
Any comparisons between AbbVie’s multibillion-dollar-per-quarter Humira (adalimumab) and its biosimilar market, and the blockbuster insulins’ biosimilars market can simply point to the need for two prices — in some cases, for each product — a higher one to entice more rebates and PBM coverage, and a handful of significantly discounted adalimumab biosimilars too.
A new report from Samsung Bioepis released this morning shows the disparities in the 12 prices across the eight competitors and Humira so far, with seven biosimilars launching on July 1. Amgen’s adalimumab biosimilar Amjevita launched first in January, but has captured just 4% of AbbVie’s market so far.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
